Andrea Pfeifer

Lausanne, VD, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo.

Elimination of tau tangles and soluble aggregates with the small molecule ACI-16664 prevents neurodegeneration in vivo.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: December 09, 2025

Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.

Correction: An Anti-β-Amyloid vaccine for treating cognitive deficits in a mouse model of down syndrome.

Journal: PloS one

Published: May 12, 2025

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

Safety and immunogenicity of two Tau-targeting active immunotherapies, ACI-35.030 and JACI-35.054, in participants with early Alzheimer's disease: a phase 1b/2a, multicentre, double-blind, randomised, placebo-controlled study.

Journal: EBioMedicine

Published: February 20, 2025

Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology.

Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology.

Journal: Nature communications

Published: November 25, 2024

A single dose of a vectorized mAb targeting TDP-43 potently inhibits the neuropathology in a model of ALS/FTD.

A single dose of a vectorized mAb targeting TDP-43 potently inhibits the neuropathology in a model of ALS/FTD.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 18, 2024

Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD.

Targeting the TDP-43 low complexity domain blocks spreading of pathology in a mouse model of ALS/FTD.

Journal: Acta neuropathologica communications

Published: April 30, 2024

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework.

Improved antibody pharmacokinetics by disruption of contiguous positive surface potential and charge reduction using alternate human framework.

Journal: mAbs

Published: July 06, 2023

Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.

Targeting amyotrophic lateral sclerosis by neutralizing seeding-competent TDP-43 in CSF.

Journal: Brain communications

Published: June 12, 2023

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

Journal: Nature communications

Published: May 17, 2023

Modeling Alzheimer's disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior.

Modeling Alzheimer's disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior.

Journal: Frontiers in neuroscience

Published: April 07, 2023

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.

Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.

Journal: Neurobiology of disease

Published: December 20, 2022

Beneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model.

Beneficial Effect of ACI-24 Vaccination on Aβ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model.

Journal: Cells

Published: November 14, 2022

Showing 1-12 of 43

Last Updated: 09/26/2026